The evidence on peptides — delivered weekly. Subscribe free →

Davalintide

moderate risk

Also: AC2307 · Amylin analog (2nd gen)

Preliminary Research Only

Davalintide is a second-generation amylin analog developed by Amylin Pharmaceuticals (now part of AstraZeneca). More potent and longer-acting than pramlintide. Phase II trials showed weight loss but development was discontinued in favor of combination approaches. Predecessor to the amylin analog class that includes cagrilintide.

Molecular Weight
~4000 Da (est)
Formula
Unknown (proprietary)
Common Dosing
Phase II dose: 0.2–0.6 mg/day SC
Category
therapeutic
Last Reviewed
2025-01-15

Reported Benefits

Weight loss

Preliminary 9 studies

Phase II: significant weight loss vs. placebo; development discontinued before Phase III.

Mechanism of Action

Amylin receptor agonist — reduces food intake via area postrema and hypothalamic satiety signaling; slows gastric emptying; reduces glucagon secretion.

Development History

Davalintide demonstrated clinical proof-of-concept for second-generation amylin agonism but was discontinued before Phase III. Lessons from its development informed cagrilintide’s design — particularly the value of amylin+GLP-1 combination approaches that became CagriSema.

Regulatory Status

Research Only

Safety Profile

Side Effects

  • •Nausea
  • •Vomiting
  • •Injection site reactions

Contraindications

  • •Pregnancy
  • •Severe GI motility disorders

Drug Interactions

  • •Insulin

Primary Uses

Weight lossObesityAmylin receptor agonism

Related Peptides

cagrilintidesemaglutide

Weekly Briefing

Regulatory updates + new study breakdowns.

For Practitioners

Do you prescribe Davalintide?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.